Form 4 for IDXX Idexx Laboratories
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-13 · accession 0000874716-25-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-18 | 2025-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | F - Tax | $444.53 | -1,222 | 83.3K | -1% | -$543.2K |
| DM | 2025-02-18 | 2025-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $0.00 | +2,747 | 83.4K | +3% | $0 |
| DM | 2025-02-18 | 2025-02-13 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | A - Grant | $0.00 | +26.1K | 217 | New | $0 |
| DM | 2025-02-18 | 2025-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $0.00 | -2,747 | 2,198 | -56% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-14 | F | D | 1,222 | $444.53 | 83,282.59 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-14 | M | A | 1,100 | $0.00 | 84,504.59 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-14 | M | A | 689 | $0.00 | 82,446.59 | D | — | — | (F1) Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024 |
| 4 | Common | Common Stock | 2025-02-14 | M | A | 958 | $0.00 | 83,404.59 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-02-13 | A | A | 25,932 | $0.00 | 25,932 | D | $459.76 · — to 2035-02-12 | 25,932 Common Stock | (F2) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. |
| 6 | Derivative | Incentive Stock Option (right-to-buy) | 2025-02-13 | A | A | 217 | $0.00 | 217 | D | $459.76 · — to 2035-02-12 | 217 Common Stock | (F3) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. |
| 7 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 689 | $0.00 | 0 | D | — · — to — | 689 Common Stock | (F4) Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022. |
| 8 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 958 | $0.00 | 958 | D | — · — to — | 958 Common Stock | (F5) Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. |
| 9 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 1,100 | $0.00 | 2,198 | D | — · — to — | 1,100 Common Stock | (F6) Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. |